chrm1

chrm1

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">chrm1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CHRM1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>chrm1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CHRM1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CHRM1 (Cholinergic Receptor Muscarinic 1) encodes the M1 muscarinic acetylcholine receptor, the most extensively studied muscarinic receptor subtype in the context of Alzheimer's disease and cognitive function. As a Gq protein-coupled receptor, CHRM1 activates phospholipase C signaling pathways that lead to increased intracellular calcium, activation of protein kinase C, and downstream effects on synaptic plasticity, gene expression, and neuronal survival.[@mg2022]

The M1 receptor is the predominant muscarinic receptor in the mammalian brain, with particularly high expression in regions critical for learning and memory, including the hippocampus and cortex. This distribution, combined with its role in activating signaling pathways important for cognition, has made CHRM1 a primary target for drug development in Alzheimer's disease.

chrm1

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">chrm1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CHRM1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>chrm1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CHRM1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CHRM1 (Cholinergic Receptor Muscarinic 1) encodes the M1 muscarinic acetylcholine receptor, the most extensively studied muscarinic receptor subtype in the context of Alzheimer's disease and cognitive function. As a Gq protein-coupled receptor, CHRM1 activates phospholipase C signaling pathways that lead to increased intracellular calcium, activation of protein kinase C, and downstream effects on synaptic plasticity, gene expression, and neuronal survival.[@mg2022]

The M1 receptor is the predominant muscarinic receptor in the mammalian brain, with particularly high expression in regions critical for learning and memory, including the hippocampus and cortex. This distribution, combined with its role in activating signaling pathways important for cognition, has made CHRM1 a primary target for drug development in Alzheimer's disease.

Despite decades of research and numerous clinical trials, M1-selective agonists have not yet achieved clinical success due to challenges including poor selectivity, side effects, and lack of sustained efficacy.[@ssm2025] However, advances in structure-based drug design and the development of positive allosteric modulators have renewed interest in CHRM1 as a therapeutic target.

This comprehensive review examines the structure, function, signaling mechanisms, expression patterns, and disease associations of CHRM1, with emphasis on its role in Alzheimer's disease pathogenesis and the ongoing efforts to develop effective M1-targeted therapeutics.

Gene and Protein Structure

Gene Organization

The CHRM1 gene (Gene ID: 1128) is located on chromosome 11q12.3 and encodes a 460-amino acid protein. Unlike some GPCRs that undergo extensive alternative splicing, CHRM1 is encoded by a single-exon gene, simplifying its expression regulation. The gene promoter contains multiple transcription factor binding sites, including elements responsive to neuronal activity and cellular stress.

Protein Architecture

The M1 muscarinic receptor exemplifies the canonical seven-transmembrane GPCR fold:

Extracellular Domains:

• N-terminal domain (1-50 amino acids): Contains potential N-linked glycosylation sites
• Extracellular loops 1-3: Form the outer entrance to the ligand-binding pocket

• Seven alpha-helices (TM1-TM7): Form the hydrophobic core
• Conserved sequence motifs: Maintain structural integrity and enable ligand binding

• Intracellular loops 1-3: Couple to G proteins and contain regulatory phosphorylation sites
• C-terminal tail: Contains serine/threonine residues for phosphorylation and β-arrestin recruitment

Ligand Binding Sites

The orthosteric binding site is located deep within the transmembrane domain, formed by residues from multiple helices. The binding pocket accommodates acetylcholine and various pharmacological ligands. Key features include:

• Conserved aspartic acid in TM3 (Asp105) as a critical anchor for agonist binding
• Multiple aromatic residues that form hydrophobic interactions with ligands
• A hydrophobic pocket that accommodates the tropine moiety of antagonist

Structural Dynamics

Crystal structures of M1 and related muscarinic receptors reveal:

• Conformational changes upon agonist binding that propagate to intracellular domains
• Multiple ligand-binding modes for agonists versus antagonists
• Allosteric sites that can be targeted for more selective modulation

Signaling Pathways

Primary Gq/11 Signaling

CHRM1 predominantly couples to Gq/11 proteins, leading to activation of phospholipase Cβ (PLCβ):

• Inositol 1,4,5-trisphosphate (IP3): Triggers calcium release from endoplasmic reticulum stores
• Diacylglycerol (DAG): Activates protein kinase C (PKC)

• Calmodulin-dependent protein kinases
• Calcineurin (PP2B)
• Various calcium-dependent transcription factors

• Phosphorylation of ion channels and receptors
• Modulation of synaptic vesicle trafficking
• Regulation of gene expression

Secondary Signaling Pathways

Beyond PLC, CHRM1 activates additional signaling cascades:

β-Arrestin Signaling

Like other GPCRs, CHRM1 can signal through β-arrestin adapters:

• Receptor internalization
• ERK activation
• Akt signaling

Expression Patterns

Brain Region Distribution

CHRM1 exhibits widespread expression throughout the central nervous system:

• Essential for synaptic plasticity and memory formation
• Critical for spatial memory and contextual learning

• Prefrontal cortex: Executive function and working memory
• Entorhinal cortex: Gateway for hippocampal inputs
• Auditory, visual, and somatosensory cortices

• Modulation of motor control circuits

• Sensory processing and relay

• Autoreceptor function

Cellular Localization

CHRM1 is expressed in:

• Pyramidal neurons: Principal excitatory neurons in cortex and hippocampus
• Interneurons: Various GABAergic inhibitory neurons
• Astrocytes: Modulation of astrocytic calcium signaling
• Microglia: Limited expression, modulation of inflammatory responses

Physiological Functions

Learning and Memory

M1 receptors are essential for multiple aspects of learning and memory:

• Long-term potentiation (LTP) in hippocampal CA1
• Long-term depression (LTD) in cortex and hippocampus
• Novel object recognition memory

• Transfer of information from short-term to long-term storage
• Contextual memory formation
• Emotional memory processing

• Maintenance of information online
• Rule learning and flexibility

Neuronal Excitability

CHRM1 modulates neuronal excitability through:

Amyloid Processing

M1 receptor activation influences amyloid precursor protein (APP) processing:

• Increases production of soluble APPα (sAPPα)
• Reduces amyloid-β generation

• TACE/ADAM17 may also be involved
• Provides neuroprotective sAPPα fragment

Tau Phosphorylation

M1 signaling intersects with tau pathology:

• Effects on tau phosphorylation sites
• Potential for both protective and pathological outcomes

Neuroprotection

M1 receptor activation can provide neuroprotective effects:

Disease Associations

Alzheimer's Disease

CHRM1 has been extensively studied in Alzheimer's disease due to:

Pathological Changes:

• Loss correlates with cognitive decline
• Affects both cortical and hippocampal regions

• Directly bind to muscarinic receptors
• Impair M1 signaling through various mechanisms
• Contribute to synaptic dysfunction

• Loss of M1-coupled signaling contributes to plasticity deficits

• Reduces M1 activation even when receptors remain

The M1 receptor has been a primary target for AD drug development:

• Challenges: Lack of selectivity, side effects, limited efficacy

• Enhance endogenous acetylcholine signaling
• Potential for improved safety profile

Schizophrenia

CHRM1 dysfunction has been implicated in schizophrenia:

Other Conditions

Clinical Development

Historical Perspective

M1 agonist development has a long history:

• Limited by peripheral side effects
• Poor brain penetration

• Improved selectivity
• Still faced efficacy and safety challenges

Current Status

Several M1-targeted approaches are in development:

Challenges

Future Directions

Interaction with Other Proteins and Pathways

G Protein Interactions

CHRM1 primarily couples to:

• Gq/11 family proteins (GNAQ, GNA14, GNA15)
• Can also engage Gβγ subunits
• Variations in coupling efficiency across brain regions

Scaffold Proteins

M1 receptors interact with various scaffolding proteins:

• GRK phosphorylation sites
• PDZ domain proteins
• Kinase complexes

Cross-Talk

CHRM1 signaling intersects with:

Animal Models

Knockout Studies

CHRM1 knockout mice exhibit:

• Impaired learning and memory
• Reduced LTP
• Altered responses to muscarinic drugs

Transgenic Models

Various models have been used to study:

• M1 overexpression effects
• Conditional knockout systems
• Disease model interactions

Molecular Mechanisms in AD

Synaptic Dysfunction

M1 signaling is critical for synaptic plasticity, and its disruption contributes to AD:

Neuronal Survival

M1 activation promotes neuronal survival through:

Amyloid Tolerance

M1 signaling may provide resilience to amyloid pathology:

Pharmacological Considerations

Agonist Pharmacology

Muscarinic agonists vary in their M1 selectivity:

Antagonist Properties

M1 antagonists include:

Allosteric Modulation

Allosteric sites offer new therapeutic opportunities:

Future Perspectives

Research Priorities

Clinical Outlook

The M1 receptor remains a compelling target for:

• Symptomatic treatment of cognitive impairment
• Potential disease-modifying effects
• Combination approaches with other mechanisms

M1 Receptor in Neuroinflammation

Emerging evidence suggests that CHRM1 plays a role in neuroinflammatory processes relevant to neurodegenerative diseases:

Microglial Activation

M1 receptors are expressed on microglia and influence inflammatory responses:

• M1 activation can enhance pro-inflammatory cytokine production
• Modulates microglial phagocytosis
• Affects antigen presentation and immune surveillance

Astrocyte Function

Astrocytic M1 receptors regulate:

• Calcium signaling and glutamate uptake
• Cytokine and chemokine release
• Metabolic support for neurons

Therapeutic Implications

Targeting M1 in neuroinflammation may provide benefits:

• Reducing excitotoxicity through astrocyte modulation
• Modulating cytokine-mediated neuronal damage
• Potential for disease modification

M1 and Circadian Rhythm

Recent research has revealed connections between M1 receptor signaling and circadian regulation:

Hippocampal Circadian Function

M1 signaling exhibits circadian variation:

• Daily rhythms in M1 receptor expression
• Effects on memory performance at different times of day
• Interactions with clock gene expression

Therapeutic Implications

Circadian considerations for M1-targeted therapy:

• Timing of drug administration
• Circadian dysfunction in AD
• Chronotherapeutic approaches

Genetic Considerations

CHRM1 Polymorphisms

Genetic variations in CHRM1 have been studied:

• Association with cognitive performance
• Response to cholinergic medications
• Risk for certain neurological conditions

Gene Expression Regulation

CHRM1 expression is regulated by:

• Neuronal activity
• Epigenetic modifications
• Transcription factors including CREB

M1 in Blood-Brain Barrier Function

M1 receptors influence blood-brain barrier (BBB) integrity:

Endothelial Function

M1 signaling affects:

• Tight junction protein expression
• Transport across the BBB
• Neuroimmune signaling at the BBB

Implications for Drug Delivery

Understanding BBB penetration is critical for:

• CNS drug development
• Targeting strategies
• Combination therapies

External Links

• [NCBI Gene - CHRM1](https://www.ncbi.nlm.nih.gov/gene/1128) - Gene database entry
• [OMIM - CHRM1](https://www.omim.org/entry/103960) - Online Mendelian Inheritance in Man
• [UniProt - CHRM1](https://www.uniprot.org/uniprotkb/P11229/entry) - Protein sequence data
• [Ensembl - CHRM1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168539) - Genomic resources
• [Allen Brain Atlas - CHRM1](https://brain-map.org/) - Gene expression data
• [PubMed - CHRM1](https://pubmed.ncbi.nlm.nih.gov/?term=CHRM1+muscarinic+receptor+Alzheimer) - Literature search

References

Pathway Diagram

The following diagram shows the key molecular relationships involving chrm1 discovered through SciDEX knowledge graph analysis:

See Also

• [POLE — DNA Polymerase Epsilon](/wiki/genes-pole) — regulates
• [VTA Dopamine Neurons in Schizophrenia](/wiki/cell-types-vta-dopamine-schizophrenia) — regulates
• [Astrocytes in Neurodegeneration](/wiki/cell-types-astrocytes-neurodegeneration) — expressed_in
• [Microglia Depletion and Repopulation Therapy](/wiki/therapeutics-microglia-depletion-repopulation) — expressed_in
• [Neuroinflammation and Microglia Pathway in Alzheimer's Disease](/wiki/mechanisms-ad-neuroinflammation-microglia-pathway) — activates
• [Neurons in Dentatorubral-Pallidoluysian Atrophy](/wiki/cell-types-dentatorubral-pallidoluysian-atrophy-neurons) — expressed_in
• [Brain-Derived Neurotrophic Factor (BDNF)](/wiki/proteins-bdnf) — inhibits
• [Brain-Derived Neurotrophic Factor (BDNF)](/wiki/proteins-bdnf) — activates

Pathway Diagram

The following diagram shows the key molecular relationships involving chrm1 discovered through SciDEX knowledge graph analysis: